-
1.发明申请
公开(公告)号：WO2023073502A1
公开(公告)日：2023-05-04
申请号：PCT/IB2022/059981
申请日：2022-10-18
Applicant: LAURUS LABS LIMITED
Inventor： SIMHADRI, Srinivas , MEKALA, Nagaraju , BUDDEPU, Srinivasa Rao , JAVVAJI, Karunakara Rao , CHEEKATI, Chiranjeevi , KUCHIPUDI, Durgaprasad , VASIREDDI, Uma Maheswer Rao
IPC: A01N43/56 , C07D401/04 , C07C231/02 , C07C237/30
Abstract: The present invention relates to methods for preparation of 2-amino-5-chloro-N-3-dimethylbenzamide compound of Formula (IV) and pyrazole-carboxylate compound of Formula (VI), an intermediates useful for preparation of certain anthranilamide compounds, for example chlorantraniliprole and/or cyantraniliprole. wherein the "R1" is selected from hydrogen or C1-4 alkyl; and each of R2-R7 is independently selected from hydrogen, halogen and C1-4 alkyl.
-
公开(公告)号：WO2022190126A1
公开(公告)日：2022-09-15
申请号：PCT/IN2022/050207
申请日：2022-03-08
Applicant: LAURUS LABS LIMITED
Inventor： NARKHEDE, Hemant Bhagwat , PIMPLE, Srikant , RAYALA, Siva Ramakrishna , RAO K, Ramgopal , VELAGA, Siva Ramakrishna , JOGALA, Satheesh
IPC: A61K31/47
Abstract: The present invention provides oral film(s) of Cystic fibrosis transmembrane conductance regulator (CFTR) modulator(s) or a pharmaceutically acceptable salt thereof. Further the present invention provides composition and process for preparing oral film(s) comprising Cystic fibrosis transmembrane conductance regulator (CFTR) modulator(s) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：WO2021260641A1
公开(公告)日：2021-12-30
申请号：PCT/IB2021/055667
申请日：2021-06-25
Applicant: LAURUS LABS LIMITED
Inventor： VELAGA, Siva Rama Krishna , RAYALA, Siva Ramakrishna , PIMPLE, Srikant , UPPALA, Ananda Haranath , DUGGI, Vamshidhar Reddy , KAVURI, Narendra Kumar
Abstract: The present invention provides oral film of HIV/Anti-retroviral drugs and its pharmaceutically acceptable salt thereof, which is useful for the treatment of HIV infections. Further the present invention provides composition and process for preparing oral film of HIV/Anti-retroviral drugs and its pharmaceutically acceptable salt thereof.
-
公开(公告)号：WO2021156811A1
公开(公告)日：2021-08-12
申请号：PCT/IB2021/050949
申请日：2021-02-05
Applicant: LAURUS LABS LIMITED
Inventor： BOLLU, Ravindra Babu , CHALLAGONDA, Venkateswar Rao , DALASINGH, Prasanta , MANDA, Ananth Reddy , KONDA, Srikanth , SATU, Narender , VASIREDDI, Uma Maheswer Rao
IPC: A61K31/00 , A61K31/04 , C07D405/12 , C07D209/12 , A61P3/00
Abstract: The present invention generally relates to processes for preparation of Tezacaftor and pharmaceutical composition comprising the same. The present invention also encompasses novel intermediates of tezacaftor, processes for its preparation and use of said intermediates in the preparation of tezacaftor.
-
5.发明申请
公开(公告)号：WO2021095015A1
公开(公告)日：2021-05-20
申请号：PCT/IB2020/060732
申请日：2020-11-15
Applicant: LAURUS LABS LIMITED
Inventor： THAIMATTAM, Ram , EDUPUGANTI, Rajesh , REGANDLA, Nageswara Rao , VASIREDDI, Uma Maheswara Rao , RADHAKRISHNAN, Suresh Babu , SEETHAMRAJU, Pavan Kumar
IPC: C07D405/12 , C07C211/52 , A61K31/404
Abstract: The present invention relates to solid forms of Tezacaftor, including its co-crystals, solvates, hydrates and/or polymorphs, processes for their preparation, pharmaceutical compositions containing the same and use of such solid forms of Tezacaftor in the preparation of another form of Tezacaftor such as amorphous form of Tezacaftor. The present invention also provides stable amorphous form of Tezacaftor, its preparation and pharmaceutical composition containing the same.
-
Patent Agency Ranking
公开(公告)号：WO2020255059A1
公开(公告)日：2020-12-24
申请号：PCT/IB2020/055782
申请日：2020-06-19
Applicant: LAURUS LABS LIMITED
Inventor： MADIVADA, BalaMurali Krishna , MEKALA, Nagaraju , KOLA, Lakshmikanth , SIMHADRI, Srinivas , ARIKATLA, Siva Lakshmi Devi
IPC: A61K38/07
Abstract: The present invention relates to a process for purification of carfilzomib free from its impurities using preparative high performance liquid chromatography (prep-HPLC).
-
7.发明申请
公开(公告)号：WO2020157644A1
公开(公告)日：2020-08-06
申请号：PCT/IB2020/050642
申请日：2020-01-28
Applicant: LAURUS LABS LIMITED
IPC: C07D409/10
Abstract: The present invention provides process for the preparation of amorphous canagliflozin substantially free of hydroperoxide impurity. The present invention also provides pharmaceutical compositions comprising amorphous canagliflozin having less than 50 ppm of hydroperoxide impurity by LC-MS and having less than about 0.1% of anti-oxidant by HPLC.
-
8.发明申请
公开(公告)号：WO2018224957A1
公开(公告)日：2018-12-13
申请号：PCT/IB2018/054013
申请日：2018-06-05
Applicant: LAURUS LABS LIMITED
Inventor： VASIREDDI, Uma Maheswar Rao , DEHURY, Sanjay Kumar , MEKALA, Nagaraju , SHAIK, Jahangeer Baba , LAGADAPATI, Srinivas
IPC: C07F9/00
Abstract: The present invention relates to process for the preparation of Empagliflozin or its co- crystals, solvates and/or polymorphs thereof. The present invention also relates to novel intermediates used therein, and process for the preparation thereof. The present invention further relates to process for preparation of amorphous and crystalline form of Empagliflozin.
-
9.发明申请
公开(公告)号：WO2020255004A1
公开(公告)日：2020-12-24
申请号：PCT/IB2020/055690
申请日：2020-06-18
Applicant: LAURUS LABS LIMITED
Inventor： THAIMATTAM, Ram , RADHAKRISHNAN, Sureshbabu , SEETHAMRAJU, Pavan Kumar , BEERAVALLI, Satheesh , PAMPANA, Uma Maheswara Rao , SHAMAKURA, Anil Kumar Reddy , BOLLU, Ravindra Babu , VASIREDDI, Uma Maheswer Rao
IPC: A61K31/4985 , C07D498/22 , A61P31/18
Abstract: The present invention generally relates to polymorphic forms of bictegravir, its salts, co-crystals, solvates or hydrates thereof and process for the preparation of the same and also relates to pharmaceutical compositions containing the same. The present invention also relates to a process for preparation of bictegravir substantially free from its diastereomer impurity.
-
10.发明申请SOLID FORMS OF LUMACAFTOR, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF 审中-公开LUMACAFTOR的固体形式，其制备方法及其药物组合物
公开(公告)号：WO2018037350A1
公开(公告)日：2018-03-01
申请号：PCT/IB2017/055074
申请日：2017-08-23
Applicant: LAURUS LABS LIMITED
IPC: A61K31/00
Abstract: The present invention generally relates to novel solid forms of lumacaftor, including amorphous form, solvates and/or polymorphs, processes for their preparation, pharmaceutical compositions containing the same and to their use in therapy.
Abstract translation: 本发明总体上涉及新型固体形式的发光体，包括无定形形式，溶剂化物和/或多晶型物，它们的制备方法，含有该化合物的药物组合物及其在治疗中的用途。
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.017 seconds)
